SEC Form 4 · accession 0001185185-16-004707
Entia Biosciences, Inc. · ERGO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Carl J Johnson
Officer — President & CEO · Director
Period of report
May 20, 2016
Accepted (ET)
May 24, 2016 · 4:56 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001408299
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 8% Conv Debenture | $0.10 | May 20, 2016 | P | — | A | May 20, 2016 | May 20, 2019 | Common Stock | 250,000 | 250,000 | D |
| Warrant | $0.125 | May 20, 2016 | P | 25,000 | A | May 20, 2016 | May 20, 2019 | Common Stock | 25,000 | 25,000 | D |